Ann: Kazia Corporate Presentation, page-16

Good conference call, but very few questions.
In answer to the Q about a flat response on the nasdaq, JG commented that the share price had quadrupled in the last 2 months, and he wants to remain on that trajectory. (what CEO wouldn't)
Still, 16x in the next two years is a fine ambition.

He also noted that the stage 1 trial will be in Europe as its close to Evotecs labs, and they will be progressing the IND application for the US at the same time.

There will be more PR done over the next few months to inform the market and investors.